Tiaa Fsb lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 111,369 shares of the medical research company’s stock after selling 1,634 shares during the period. Tiaa Fsb’s holdings in Thermo Fisher Scientific were worth $30,484,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in TMO. Capital Financial Planning LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at $27,000. Hanson McClain Inc. raised its position in Thermo Fisher Scientific by 263.9% in the 4th quarter. Hanson McClain Inc. now owns 131 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 95 shares during the last quarter. Truvestments Capital LLC purchased a new stake in Thermo Fisher Scientific in the 1st quarter valued at $29,000. Capital Investment Advisory Services LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $35,000. Finally, Liberty Wealth Management LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $35,000. Hedge funds and other institutional investors own 88.66% of the company’s stock.
In other news, SVP Gregory J. Herrema sold 19,808 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $253.29, for a total transaction of $5,017,168.32. Following the completion of the sale, the senior vice president now owns 25,688 shares of the company’s stock, valued at $6,506,513.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $266.00, for a total value of $665,000.00. The disclosure for this sale can be found here. Insiders have sold 36,927 shares of company stock valued at $9,388,124 in the last three months. Corporate insiders own 0.49% of the company’s stock.
Shares of NYSE:TMO opened at $266.83 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.73 and a quick ratio of 1.24. Thermo Fisher Scientific Inc. has a 52-week low of $202.83 and a 52-week high of $282.98. The company has a market capitalization of $110.75 billion, a price-to-earnings ratio of 24.00, a PEG ratio of 1.83 and a beta of 1.13.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 30th. The medical research company reported $3.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.19 by $0.06. Thermo Fisher Scientific had a net margin of 12.06% and a return on equity of 16.86%. The company had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.26 billion. During the same quarter last year, the company earned $2.79 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 7.6% on a year-over-year basis. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 12.15 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, April 16th. Stockholders of record on Friday, March 15th were given a dividend of $0.19 per share. The ex-dividend date was Thursday, March 14th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.28%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.83%.
A number of equities analysts have recently weighed in on the stock. Bank of America reaffirmed a “buy” rating and set a $300.00 price target (up from $285.00) on shares of Thermo Fisher Scientific in a research note on Tuesday. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $310.00 price objective on the stock in a research note on Tuesday, April 9th. Deutsche Bank increased their price objective on shares of Thermo Fisher Scientific from $275.00 to $300.00 and gave the company a “buy” rating in a research note on Friday, March 22nd. Robert W. Baird increased their price objective on shares of Thermo Fisher Scientific from $270.00 to $288.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Finally, BTIG Research increased their price objective on shares of Thermo Fisher Scientific to $310.00 and gave the company a “buy” rating in a research note on Tuesday, March 26th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and an average target price of $289.92.
COPYRIGHT VIOLATION NOTICE: “Tiaa Fsb Reduces Position in Thermo Fisher Scientific Inc. (TMO)” was first published by Fairfield Current and is owned by of Fairfield Current. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/04/17/tiaa-fsb-reduces-position-in-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Story: How to Trade Using Analysts Ratings
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.